Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

Smart microneedles using advanced tech could improve psoriasis treatment.

This review discusses recent findings on cellular antioxidant responses to oxidative stress and their implications for treating various human diseases but reports no new clinical results.

This study found that PBMCsec has anti-fibrotic effects on mouse and human skin scars by regulating pro-fibrotic gene expression and inhibiting myofibroblast differentiation and elastic fiber breakdown.

This study identified orally available itaconate derivatives that improve cellular permeability and bioavailability, with specific POC-based prodrugs showing significant inhibition of inflammatory cytokines in human epidermal keratinocytes and favorable oral pharmacokinetics, highlighting their potential for treating systemic and skin disorders.

In this study, researchers found that 4-Octyl itaconate (4-OI) inhibited cisplatin-induced ferroptosis and protected auditory cells by activating the NRF2/HO-1 signaling pathway, suggesting a potential therapeutic approach for reducing hearing loss associated with cisplatin treatment.

This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

This study conducted molecular docking and ADME property analysis on 144 newly designed isatin analogs, suggesting they exhibit lead-like properties for targeting EGFR enzymes.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This review examines the role of topoisomerase-interacting drugs in cancer treatment and emphasizes the importance of understanding their mechanisms for clinical development, but it presents no new results.

This study found that arylhydantoin and arylthiohydantoin derivatives with hydroxybutyl or methyl side-chains showed superior androgen receptor binding affinity and may serve as promising radioiodinated AR ligands.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This review explores the synthesis and potential of azasteroids as novel drugs, discussing challenges in their production and reporting no new clinical results.

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

This study identified certain benzopyran derivatives with a bulky tert-butyloxycarbonylamino group as effective KATP channel openers that inhibit insulin secretion in rat pancreatic islets.

This study reports a novel method for synthesizing substituted hydantoins, including the anticonvulsant drug ethotoin, using safer reagents and fewer steps compared to conventional protocols.

This article updates a prior work on pharmacophore modeling and highlights the advances in 3D database searching technologies for drug design, without presenting new research findings.

This study found that several newly synthesized dihydrobenzopyran compounds inhibited insulin secretion and had vasorelaxant activity, with some more potent than reference KATP channel activators, though compound 21 functioned as a Ca2+ entry blocker.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

In this study, isatin-gallate hybrids were synthesized and assessed, with compound 3b showing significant in vitro antioxidant and cytotoxic activities, and the series displaying moderate efficacy in inhibiting coronavirus activity through in silico analysis.

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This study synthesized and verified the structures of Setipiprant's major and minor metabolites, confirming their regio- and enantioselectivity from earlier proposals in a clinical study.

This study reports that 2-(1-Adamantyl)-4H-thiochromen-4-on-6-O-sulfamate is the most potent steroid sulfatase inhibitor identified so far, exhibiting 170-fold higher activity than the lead compound estrone sulfamate.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This review discusses strategies for treating hormone-dependent prostate diseases and synthesizes a range of potential 5α-reductase inhibitors, but experimental evaluation of these compounds was not completed.

This study suggests that itraconazole may significantly improve therapy for aspergillosis, with 12 out of 15 evaluable patients responding to the treatment.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.